Mail

ANIX - Anixa Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

3.1160

-0.1940 (-5.86%)

As of 2:50PM EST. Market open.

Stock chart is not supported by your current browser

Previous Close	3.3100
Open	3.3000
Bid	3.1000 x 1000
Ask	3.1100 x 800
Day's Range	3.1029 - 3.3000
52 Week Range	2.7400 - 5.4700
Volume	54,551
Avg. Volume	72,096

Market Cap	64.879M
Beta (5Y Monthly)	0.79
PE Ratio (TTM)	N/A
EPS (TTM)	-0.5890
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	8.00

All

News

Press Releases

PR Newswire
Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Department of Immunology at Moffitt Cancer Center, Anixa's development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program.
Zacks
Top Ranked Momentum Stocks to Buy for February 11th
Top Ranked Momentum Stocks to Buy for February 11th
PR Newswire
Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) Special Conference on Advances in Liquid Biopsies. The presentation will review data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation test.
Simply Wall St.
Investors Who Bought Anixa Biosciences (NASDAQ:ANIX) Shares Three Years Ago Are Now Down 38%
It's nice to see the Anixa Biosciences, Inc. (NASDAQ:ANIX) share price up 14% in a week. But that cannot eclipse the...
PR Newswire
Anixa Biosciences to Present at Biotech Showcase 2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that its chief executive officer, Dr. Amit Kumar, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.
PR Newswire
Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the commercial launch of its Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC), the first test developed with the Cchek™ artificial intelligence driven, flow cytometry based, liquid biopsy technology platform.
PR Newswire
Anixa Biosciences to Host Conference Call to Discuss Plans for 2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that it will hold a conference call on December 17, 2019 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss the progress made and the future plans for its CchekTM artificial intelligence based cancer diagnostic test and its CAR-T based ovarian cancer therapeutic and breast cancer vaccine programs.
PR Newswire
Anixa Biosciences Provides Update on CAR-T Program
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced an update regarding the chimeric antigen receptor T-cell (CAR-T) technology it is developing with its partner, Moffitt Cancer Center.
PR Newswire
Anixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from its ongoing studies utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology will be presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS).
PR Newswire
Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the addition of Genesis Research, LLC to the ongoing Cchek™ prostate cancer detection study.
PR Newswire
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Nov. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek™ early prostate cancer detection study. UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test.
PR Newswire
Anixa Biosciences Announces Collaboration with Idaho Urologic Institute on Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , Nov. 20, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced ...
PR Newswire
Anixa Biosciences Announces Presentation at Cell Symposia: Hallmarks of Cancer
SAN JOSE, Calif. , Nov. 7, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced ...
PR Newswire
Anixa Biosciences Announces Patent Issued for its Breast Cancer Vaccine
The lead inventor on the patent is Dr. Vincent Tuohy of the Department of Inflammation and Immunity at the Cleveland Clinic's Lerner Research Institute and also the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research. The patent is assigned to the Cleveland Clinic and Anixa Biosciences is the exclusive world-wide licensee.
Simply Wall St.
What Kind Of Shareholders Own Anixa Biosciences, Inc. (NASDAQ:ANIX)?
A look at the shareholders of Anixa Biosciences, Inc. (NASDAQ:ANIX) can tell us which group is most powerful. Large...
PR Newswire
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
SAN JOSE, Calif. , Oct. 28, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced ...
PR Newswire
Anixa Biosciences Announces Collaboration with Urology San Antonio on Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , Oct. 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced ...
PR Newswire
Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)
SAN JOSE, Calif. , Oct. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the acceptance ...
PR Newswire
Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts
SAN JOSE, Calif. , Oct. 15, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced ...
PR Newswire
Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board
SAN JOSE, Calif., Oct. 10, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the appointment of Ian H. Frazer, MD, AC, FRS, FAA, to its Scientific Advisory Board. Dr. Frazer is a leading immunologist recognized as one of the first scientists to study the link between immunity to human papillomavirus (HPV) infection and cervical cancer.
PR Newswire
Anixa Biosciences Announces University of Maryland School of Medicine to Join Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , Sept. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that Mohummad ...
Simply Wall St.
Should You Worry About Anixa Biosciences, Inc.'s (NASDAQ:ANIX) Cash Runway?
Anixa Biosciences, Inc. (NASDAQ:ANIX) continues its loss-making streak, announcing negative earnings for its latest...
PR Newswire
Anixa Biosciences Commences Collaboration with Potomac Urology Center on Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , Sept. 19, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that Potomac ...
PR Newswire
Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree
SAN JOSE, Calif., Sept. 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, congratulates H. Michael Shepard, Ph.D., a member of Anixa's Scientific Advisory Board, as a recipient of the 2019 Lasker-DeBakey Clinical Medical Research Award in recognition of his research work in improving patient lives in the field of oncology. Dr. Shepard is one of three scientists accepting this year's Lasker award for the development of the anti-cancer drug Herceptin (trastuzumab) for the treatment for HER2-positive breast cancer. Herceptin has also been proven to be effective in treating ovarian and gastric cancer patients.
PR Newswire
Anixa Biosciences to Present at Two Upcoming Investor Conferences
SAN JOSE, Calif. , Aug. 26, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced its participation ...